Protara Therapeutics
TARA
82 hedge funds and large institutions have $114M invested in Protara Therapeutics in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 26 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
8% more funds holding
Funds holding: 76 → 82 (+6)
8% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 26
9.05% less ownership
Funds ownership: 77.02% → 67.97% (-9%)
30% less call options, than puts
Call options by funds: $183K | Put options by funds: $261K
64% less capital inflows, than outflows
Capital inflows: $5.98M | Capital outflows: $16.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Driehaus Capital Management
Chicago,
Illinois
|
+$1.44M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$995K |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$589K |
| 4 |
Renaissance Technologies
New York
|
+$535K |
| 5 |
Janus Henderson Group
London,
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
-$3.15M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.59M |
| 3 |
Woodline Partners
San Francisco,
California
|
-$2.58M |
| 4 |
Stempoint Capital
New York
|
-$2.53M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.21M |
TARA Hedge Fund Activity: Q3 2025 in Review
82 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2025, worth a combined $114M — up 27% from $90.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TARA positions and 8 closed out — a net gain of 7 holders — while 24 added to existing stakes and 26 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $1.44M. The largest seller was RA Capital Management, exiting entirely with an estimated $3.15M sold.
- 82 institutional investors held Protara Therapeutics (TARA) as of Q3 2025, up from 76 in Q2 2025.
- Funds reported $114M of Protara Therapeutics stock for Q3 2025, up 27% quarter-over-quarter.
- 15 funds opened new Protara Therapeutics positions in Q3 2025 and 8 closed out, a net change of +7 holders.
- The largest Protara Therapeutics buyer in Q3 2025 was Driehaus Capital Management, an estimated $1.44M added.
- The largest Protara Therapeutics seller in Q3 2025 was RA Capital Management, an estimated $3.15M sold.
Based on aggregated 13F filings for Q3 2025.